Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Stratified, Randomized, Double-Blind, Multicenter, Non-Inferiority Study to Evaluate the Safety and Immunogenicity of a Cell-based Quadrivalent Subunit Influenza Virus Vaccine and Cell-based Trivalent Subunit Influenza Virus Vaccines in Adults Ages greater than or equal to 18 Years of Age

Next Previous
Trial Profile

A Phase III, Stratified, Randomized, Double-Blind, Multicenter, Non-Inferiority Study to Evaluate the Safety and Immunogenicity of a Cell-based Quadrivalent Subunit Influenza Virus Vaccine and Cell-based Trivalent Subunit Influenza Virus Vaccines in Adults Ages greater than or equal to 18 Years of Age

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 May 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 23 May 2016 According to a Seqirus media release, the US FDA has approved FLUCELVAX QUADRIVALENT (Influenza Vaccine) for prevention against two influenza A viruses and two B viruses recommended by WHO and FDA in people aged four years and older.
  • 31 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 09 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top